- The P-III FREEDOM study (Study 342) results involve assessing of Fycompa (2mg/day & 4mg/day) as monothx.in 89 patients with newly diagnosed or untreated POS aged ≥12 yrs.
- The P-III FREEDOM study results: @26wks. 4mg/day, 63% of patients achieved seizure freedom for POS; 65% of patients with generalized seizures are convulsive seizure free
- Fycompa is a selective, non-competitive AMPA receptor antagonist, available as a film-coated tablet in 2mg, 4mg, 6mg, 8mg, 10mg and 12mg and as a 0.5 mg/mL oral suspension formulation and is approved in 55 countries for multiple epileptic indications
Click here to read full press release/ article | Ref: PRNewsWire | Image: Telangana Today